AKTS
Price
$20.90
Change
+$20.86 (+52150.00%)
Updated
Feb 3 closing price
Capitalization
1.09B
Intraday BUY SELL Signals
SPRY
Price
$10.15
Change
-$1.43 (-12.35%)
Updated
Feb 3 closing price
Capitalization
1B
43 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AKTS vs SPRY

Header iconAKTS vs SPRY Comparison
Open Charts AKTS vs SPRYBanner chart's image
Aktis Oncology
Price$20.90
Change+$20.86 (+52150.00%)
Volume$298.9K
Capitalization1.09B
ARS Pharmaceuticals
Price$10.15
Change-$1.43 (-12.35%)
Volume$1.04M
Capitalization1B
AKTS vs SPRY Comparison Chart in %
SPRY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AKTS vs. SPRY commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKTS is a StrongBuy and SPRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (AKTS: $20.90 vs. SPRY: $10.15)
Brand notoriety: AKTS and SPRY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKTS: 61% vs. SPRY: 62%
Market capitalization -- AKTS: $1.09B vs. SPRY: $1B
AKTS [@Biotechnology] is valued at $1.09B. SPRY’s [@Biotechnology] market capitalization is $1B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKTS’s FA Score shows that 0 FA rating(s) are green whileSPRY’s FA Score has 0 green FA rating(s).

  • AKTS’s FA Score: 0 green, 5 red.
  • SPRY’s FA Score: 0 green, 5 red.
According to our system of comparison, AKTS is a better buy in the long-term than SPRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SPRY’s TA Score shows that 3 TA indicator(s) are bullish.

  • SPRY’s TA Score: 3 bullish, 7 bearish.

Price Growth

AKTS (@Biotechnology) experienced а -1.51% price change this week, while SPRY (@Biotechnology) price change was -3.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.

Reported Earning Dates

SPRY is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Biotechnology (-4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKTS($1.09B) has a higher market cap than SPRY($1B).
AKTSSPRYAKTS / SPRY
Capitalization1.09B1B109%
EBITDAN/A-90.79M-
Gain YTDN/A-12.876-
P/E RatioN/A151.25-
RevenueN/A143M-
Total CashN/A288M-
Total DebtN/A97.8M-
FUNDAMENTALS RATINGS
AKTS: Fundamental Ratings
AKTS
OUTLOOK RATING
1..100
68
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
PROFIT vs RISK RATING
1..100
59
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
SPRY
RSI
ODDS (%)
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 15 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
SPRY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DUSB50.79N/A
N/A
Dimensional Ultrashort Fixed Income ETF
JPMB40.23-0.01
-0.02%
JPMorgan USD Emerging Mkts Svr Bd ETF
DDTS21.50-0.07
-0.33%
Innovator Eq Dual Drctnl 10 Buf ETF -Sep
VLLU24.23-0.11
-0.46%
Harbor AlphaEdge Large Cap Value ETF
DAPP17.15-0.24
-1.38%
VanEck Digital Trfmt ETF

AKTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKTS has been loosely correlated with CGON. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if AKTS jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKTS
1D Price
Change %
AKTS100%
-4.91%
CGON - AKTS
34%
Loosely correlated
-3.28%
NBY - AKTS
33%
Loosely correlated
-32.16%
ZNTL - AKTS
27%
Poorly correlated
+12.35%
SPRY - AKTS
27%
Poorly correlated
-1.46%
CRDO - AKTS
24%
Poorly correlated
-7.21%
More

SPRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRY has been loosely correlated with LPCN. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRY jumps, then LPCN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRY
1D Price
Change %
SPRY100%
-1.46%
LPCN - SPRY
63%
Loosely correlated
-7.33%
REPL - SPRY
31%
Poorly correlated
+5.81%
ACAD - SPRY
30%
Poorly correlated
-5.24%
CLDX - SPRY
29%
Poorly correlated
+2.07%
EYPT - SPRY
29%
Poorly correlated
-3.69%
More